Key clinical point: Secukinumab was associated with rapid and significant clinical improvement as measured with ASAS20, compared with placebo.
Major finding: At week 12, ASAS20 responses were achieved in 65% of patients given secukinumab and 31.3% of patients given placebo (P less than .0001).
Data Source: The double-blind, placebo controlled, phase 3b MAXIMISE trial of 498 patients.
Disclosures: Dr. Baraliakos reported multiple financial relationships with pharmaceutical companies, including Novartis, which sponsored this trial.
Ann Rheum Dis. Jun 2019;78(Suppl2):195-6. Abstract OPO235. doi: 10.1136/annrheumdis-2019-eular.2932.